Novartis Finalizes $10.91 Billion Multi-Tranche Debt Offering to Refinance Avidity Biosciences Acquisition

summarizeSummary

Novartis finalized an $10.91 billion multi-tranche debt offering to refinance the bridge loan for its Avidity Biosciences acquisition, detailing specific interest rates and maturities.

check_boxKey Events

• Debt Offering Finalized

  Novartis Capital Corporation, guaranteed by Novartis AG, finalized an $10.91 billion multi-tranche debt offering, following the announcement on March 16, 2026.

• Multi-Tranche Structure

  The offering includes a $500 million floating rate note due 2029 and six fixed-rate notes totaling $10.49 billion, with maturities ranging from 2029 to 2056 and interest rates from 4.100% to 5.700%.

• Use of Proceeds

  The net proceeds will be used for general corporate purposes outside of Switzerland, specifically to repay outstanding borrowings under the bridge loan for the acquisition of Avidity Biosciences.

• Guaranteed by Novartis AG

  All notes are fully and unconditionally guaranteed by Novartis AG, ranking equally with its other senior, unsecured debt obligations.

auto_awesomeAnalysis

Novartis Capital Corporation, guaranteed by Novartis AG, has finalized the detailed terms and pricing for its substantial $10.91 billion multi-tranche debt offering. This significant capital raise is primarily intended to refinance the bridge loan used for the recent acquisition of Avidity Biosciences. The successful execution of such a large debt offering demonstrates strong access to capital markets and provides financial stability for the company's strategic initiatives, including managing its acquisition-related debt. While increasing overall indebtedness, this move is a planned financial action to optimize the capital structure following a major acquisition.